Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study comparing GPO Dapagliflozin 10 mg tablet and Forxiga in healthy adults under fasting condition
TCTR20251022010Phase 1Completed
- Sponsor
- Government Pharmaceutical Organization
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dapagliflozin (2 arms), sponsored by Government Pharmaceutical Organization. Primary endpoint: Primary pharmacokinetic bioequivalence. Started Nov 2025; status: completed.
02
Drugs
dapagliflozin
Beyond the preview
Go deeper on TCTR20251022010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20251022010.